Diabetes therapy trials with inhaled insulin

Bibliography

• TURNER R: The UK Prospective Diabetes Study. A review. Diabetes Care (1998) 21(12 Suppl. 3):C35-C38.
   PubMed Web of Science ®Google Scholar
• DIABETES CONTROL ANDCOMPLICATIONS TRIAL GROUP: The effect of intensive treatment of diabetes on the development and progression of long term complications. N. Engl. J. Med. (1993) 329(14):977-986.
   PubMed Web of Science ®Google Scholar
• HOME P: Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with Type 2 diabetes. Curr. Med. Res. Opin. (2005) 21(7):989-998.
   Web of Science ®Google Scholar
• KORYTKOWSKI M: When oral agents fail; practical barriers to starting insulin. Int. J. Obes. (2002) 26(Suppl. 3):S18-S24.
   Google Scholar
• GANSSLEN M: Uber inhalation von insulin. Klin. Wochensubcutaeoushr. (1925) 4:71.
   Google Scholar
• PATTON JS, NAGARAJAN S: Inhaled insulin. Adv. Drug Deliv. Rev. (1999) 135(2-3):235-247.
   Google Scholar
• BYRON PR: Drug delivery via the respiratory tract. J. Aerosol Med. (1994) 7(1):49-75.
   PubMedGoogle Scholar
• SCHUSTER J, LLOYD RR, LLOYD P: The AERx aerosol delivery system. J. Pharm. Res. (1997) 14(3):354-357.
   Google Scholar
• ANONYMOUS: Insulin inhalation: NN 1998. Drugs RD (2004) 5(1):46-49.
   PubMedGoogle Scholar
• BRUNNER G, BALENT B, ELLMERER M et al.: Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patients. Diabetologia (2001) 44(3):305-308.
   PubMed Web of Science ®Google Scholar
• AN B, REINHARDT RR: Effects of different durations of breath holding after inhalation of insulin using the AERx insulin diabetes management system. Clin. Ther. (2003) 25:2233-2244.
   Google Scholar
• BRUNNER G, BALENT B, ELLMERER M et al.: Dose–response relation of liquid aerosol inhaled insulin in Type I diabetic patients. Diabetologia (2001) 44(3):305-308.
   PubMed Web of Science ®Google Scholar
• HIMMELMANN A, JENDLE J, MELLEN A, PETERSEN AH, DAHL UL, WOLLMER P: The impact of smoking on inhaled insulin. Diabetes Care (2003) 26(3):677-682.
   PubMed Web of Science ®Google Scholar
• HENRY RR, CHU MS, KIM N et al.: Young and elderly Type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison. J. Clin. Pharmacol. (2003) 43(11):1228-1234.
   Google Scholar
• HENRY RR, HOWLAND WC III, CHU N, KIM D, AN B, REINHARDT RR: Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care (2003) 26(3):764-769.
   PubMed Web of Science ®Google Scholar
• McELDUFF A, KAM PC, CLAUSON P: Influence of acute respiratory tract infection on the absorption of inhaled insulin using the AERx insulin Diabetes Management System. Br. J. Clin. Pharmacol. (2005) 59(5):546-551.
   Web of Science ®Google Scholar
• KAPITZA C, HOMPESCH M, SCHARLING B, HEISE T: Intrasubject variability of inhaled insulin in Type 1 diabetes: a comparison with subcutaneous insulin. Diabetes Technol. Ther. (2004) 6(4):466-472.
   Google Scholar
• HERMANSEN K, PETERSEN AH, BELLAIRE S, ADAMSON U: Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12 week proof of concept trial in patients with Type 2 diabetes. Diabetes Care (2004) 27(1):162-167.
   PubMed Web of Science ®Google Scholar
• OSBORNE R: Novo Nordisk agrees to $55 M for Aradigm’s insulin program. BioWorld Today (2004) 15(189):1-2.
   Google Scholar
• DUNBAR C, SOMMERER K, DE LONG M, VERMA A, BATYCKY R: In vitro and in vivo dose delivery characteristics of large porous particles for inhalation. Int. J. Pharmaceutics (2002) 245:179-189.
   PubMed Web of Science ®Google Scholar
• WOLFF RK, WROBLEWSKI VJ, ENGELHARDT JA, DEAVER DR, SHAW ME: 13-week inhalation study to characterize the toxicity and PK/PD of a human inhaled insulin powder (HIIP) in beagle dogs. Diabetes (2004) 53(6 Suppl. 2):A115-A116.
   Google Scholar
• DE LONG M, DAWSON M, MEYER T, SOMMERER K, DUNBAR C: Dose delivery characteristics of the AIR® pulmonary delivery system over a range of inspiratory flow rates. J. Aerosol Med. (2005) 18(4):452-459.
   PubMedGoogle Scholar
• RAVE K, DE LA PENA A, SEGER M, HEINEMANN L, BATYCKY R, MUCHMORE D: Dose–response and dose equivalency of human insulin inhalation powder (HIIP) using the Lilly/Alkermes inhaled insulin system compared to subcutaneous (SC) insulin Lispro. Diabetes (2005) 54(6 Suppl. 1):A89.
   Google Scholar
• RAVE KM, DE LA PENA A, SEGER M et al.: Dose–response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care (2005) 28(10):2400-2405.
   PubMed Web of Science ®Google Scholar
• GARG S, MUCHMORE D, DE LA PENA A, SUN B, SILVERMAN B: Safety and efficacy of preprandial human insulin inhalation powder (HIIP) delivered by the Lilly/Alkermes inhaled insulin system versus injectable insulin in patients with Type 1 diabetes (T1D). Diabetes (2005) 54(6 Suppl. 1):A89.
   Google Scholar
• ROSENSTOCK J, DE LA PENA A, SUN B, SILVERMAN B: The safety and efficacy of human insulin powder HIIP) versus injectable insulin in patients with Type 1 diabetes (T1D). Diabetologia (2005) 48(Suppl. 1):A30.
   Google Scholar
• SKYLER JS, KOURIDES IA, LANDSCHULZ WH, BALAGTAS CC, CHENG SL, GELFAND RA: Efficacy of inhaled human insulin in Type 1 diabetes mellitus: a randomized proof-of-concept study. Lancet (2001) 357(9253):331-335.
   PubMed Web of Science ®Google Scholar
• WHITE S, CHEU S, CONLEY PW et al.: Exubera: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol. Ther. (2005) 7(12):896-906.
   Google Scholar
• RAVE K, HEINEMANN L, SHA S, BECKER RH, WILLAVIZE SA, HEISE T: Time–action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care (2005) 28(5):1077-1082.
   PubMed Web of Science ®Google Scholar
• EDGERTON DS, SCOTT M, BOWEN L et al.: Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes (2005) 54(4):1164-1170.
   PubMed Web of Science ®Google Scholar
• FINEBERG SE, FINCO-KENT D, LIU C, KRASNER A: Antibody response to inhaled insulin in patients with Type 1 or Type 2 diabetes. An analysis of initial Phase II and III inhale insulin (Exubera) trials and a two-year extension trial. J. Clin. Endocrinol. Metab. (2005) 90(6):3287-3294.
   Google Scholar
• HEISE T, TYDEK C, STEPHAN JA et al.: The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. Diabetes Care (2005) 28(9):2161-2169.
   PubMed Web of Science ®Google Scholar
• SKYLER JS, RASKIN P, YALE JF, BARRETT E, GERICH JE, GERSTEIN HC: Inhaled Insulin Phase III Type 1 Diabetes Study Group: use of inhaled insulin in a basal/bolus regimen in Type 1 subjects: a 6-month, randomized, comparative trial. Diabetes Care (2005) 28(7):1630-1635.
   PubMed Web of Science ®Google Scholar
• DEFRONZO RA, CEFALU WT, PULLMAN J, LERMANN S, BODE BW, PHILLIPS LS: Exubera Phase III Study Group: efficacy of inhaled insulin in patients with Type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care (2005) 28(8):1922-1928.
   PubMed Web of Science ®Google Scholar
• ROSENSTOCK J, MURPHY LJ, CLEMENT SC et al.: Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in Type 2 diabetes: a randomized controlled trial. Ann. Intern. Med. (2005) 143(18):549-558.
   PubMed Web of Science ®Google Scholar
• HOLLANDER PA, TOWE R, MEHTA AE et al.: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with Type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care (2004) 27(10):2356-2362.
   PubMed Web of Science ®Google Scholar
• FREEMANTLE N, DUHOT D, HOMPESCH M et al.: Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with Type 2 diabetes. Diabetes Care (2005) 28(2):427-428.
   PubMed Web of Science ®Google Scholar
• ROSENSTOCK J, BOLINDER B, GERBER RA: Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with Type 1 or Type 2 diabetes. Diabetes Care (2004) 27(6):1318-1323.
   PubMed Web of Science ®Google Scholar
• DUMAS R, RIESE RJ, TEETER JG: Exubera® is well tolerated and achieves tight glycemic control in patients with Type 1 diabetes. Diabetes (2005) 54(Suppl. 1):A87.
   Google Scholar
• DUMAS R, RIESE RJ: TEETER J G: Inhaled insulin (Exubera™) achieves tight glycemic control and is well tolerated in patients with Type 1 diabetes. Diabetologia (2005) 48(Suppl. 1):A30.
   Google Scholar
• CEFALU WT: Long-term use of Exubera® in Type 2 diabetes: observations on glycemic control, pulmonary function and antibody formation. Diabetes (2005) 54(Suppl. 1):A88.
   Google Scholar
• LABIRIS R, KAWABATA T, SADRZADEH N et al.: Validation of radiolabelled insulin powder for Exubera® studies. Diabetes (2005) 54:A106.
   Google Scholar
• TESTA MA, HAYES JF, SCRANTON RE, SIMONSON DC: An international trial of sulfonylurea plus either metformin or Exubera: impact on quality of life and treatment satisfaction. Diabetologia (2004) 47(Suppl. 1):A5.
   Google Scholar
• SIMONSON DC, HAYES JF, SCRANTON RE, TESTA MA: Improving quality of life in Type 2 diabetes when Exubera is added after failure on metformin: a multicenter, international trial. Diabetologia (2004) 47(Suppl. 1):A311.
   Google Scholar
• SKYLER JS: Long term efficacy, and safety of inhaled insulin after 4 years of continuous therapy. Diabetologia (2004) 47(Suppl. 1):A311.
   Google Scholar
• DEFRONZO RA: Efficacy and safety of inhaled insulin (Exubera) compared with rosiglitazone in Type 2 diabetes patients not optimally controlled on diet and exercise, randomized, comparative trial. Diabetes (2003) 52(Suppl. 1):A38.
   PubMed Web of Science ®Google Scholar
• BECKER R, FRICKE SS, PIECHATZEK A: The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin (Exubera). Diabetes (2003) 52(6 Suppl. 1):A37.
   Google Scholar
• STEINER S, WILSON BR, HARZER O, HEINEMANN L, RAVE K: Technosphere/insulin-proof of concept study with a new insulin formulation for pulmonary delivery. Exp. Clin. Endocrinol Diabetes (2002) 110(1):17-21.
   Google Scholar
• BOSS AH, CHEATHAM WW, TIM H: Inhaled technosphere/insulin: glucose elimination at the right time? Diabetes (2005) 54(6 Suppl. 1):A109.
   Google Scholar
• BOSS AH, RAVE K, CHEATHAM WW: The variability and time–action profile of inhaled technosphere/insulin compares favorably to that of subcutaneous human regular insulin. Diabetes (2005) 54(6 Suppl. 1):A88.
   Google Scholar
• BOSS A, CHEATHAM W: Mimicry of the early phase insulin response in humans with rapidly available inhaled insulin accelerates postprandial glucose disposal compared to slower bioavailable insulin. Diabetes (2005) 54(6 Suppl.1):A333.
   PubMed Web of Science ®Google Scholar
• LAUREANO RT, CARBALLO I, ROUSSEAU K et al.: rapid absorption and clearance of insulin from the lung following pulmonary administration of technosphere/insulin; a pharmacokinetic study in a rat model. Diabetes (2005) 54(6 Suppl. 1):A110.
   Google Scholar
• KRUEGER P, LEINER KA, CARBALLO I, HARRIS E, WOODS R, GELBER C: Toxicological profile of pulmonary drug delivery agent. Diabetes (2004) 53(6 Suppl. 2):A110.
   Google Scholar
• LEINER KA, DAUKAS K, MENKIN P et al.: The pharmacokinetic profile of insulin administered by inhalation in the rat. Diabetes (2004) 53(6 Suppl. 2):A111.
   Google Scholar
• ROSENSTOCK J, RIVERA-SCHAUB T, OTTERBACH K et al.: A randomized, double-blind, placebo controlled study of the efficacy and safety of inhaled technosphere insulin in patients with Type 2 diabetes (T2DM). Diabetes (2005) 54(6 Suppl. 1):A88.
   Google Scholar
• CHEATHAM WW, BOSS AH, FORST T, PFÜTZNER A: A novel pulmonary insulin formulation replicates first phase insulin release and reduces s-proinsulin levels. Diabetes (2004) 53(6 Suppl. 2):A107.
   Google Scholar
• PFUETZNER A, MEYER T, HAUSSERMANN S et al.: Lung distribution of radiolabelled technosphere/insulin. Diabetes (2003) 52(6 Suppl. 1):A107.
   Google Scholar
• HAUSMANN M, HEINEMANN L, BUCHWALD A, HEISE T: Add-on therapy with Kos inhaled insulin using a metered dose inhaler is as efficacious as add-on therapy with Lantus® in poorly controlled Type 2 diabetic patients treated with sulfonylurea or metformin. Diabetes (2005) 54(6 Suppl. 1):A102-A103.
   Google Scholar
• HAUSMANN M, HEINEMANN L, BUCHWALD A, HEISE T: Add-on therapy with Kos inhaled insulin using a metered dose inhaler is as efficacious as add-on therapy with Lantus® in poorly controlled Type 2 diabetic patients treated with sulfonylurea or metformin. Diabetologia (2005) 48(Suppl. 1):A297.
   Google Scholar
• LI J, WONG S, LEUNG E, SU SL: Alveair™, a new pulmonary insulin-its glucose responses compared to Aspar insulin intravenous injection in normal rats and its insulin profile in guinea pigs. Diabetes (2005) 54(6 Suppl. 1):A112.
   Google Scholar
• LEUNG FK, LI J, LEUNG E: Dose–response of Alveair Insulin in normal rats-a new pulmonary insulin formulation. Diabetes (2004) 53(6 Suppl. 1):A468.
   Google Scholar
• LEUNG FK, LI J, LEUNG E, LIU N: Insulin pharmacokinetic estimates of Alveair® – anew pulmonary insulin formulation. Diabetes (2005) 54(6 Suppl. 1):A467-A468.
   Google Scholar
• LEUNG FK, LIN CC, WONG S et al.: Alveair®, a new pulmonary insulin -its first human trial and the preclinical animal data correlation. Diabetes (2004) 53(6 Suppl. 2):A111.
   Google Scholar
• HSIA CCW, RASKIN P: The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am. J. Med. (2005) 118:205-211.
   PubMed Web of Science ®Google Scholar
• SKYLER JS: WEINSTOCK, RUTH S et al.: The Inhaled Insulin Phase III Type 1 Diabetes Study Group: use of inhaled insulin in a basal/bolus insulin regimen in Type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care (2005) 28(7):1630-1635.
   PubMed Web of Science ®Google Scholar
• SADRI H, MacKEIGAN LD, LEITER LA, FINARSON TR: Willingness to pay for inhaled insulin: a contingent valuation approach. Parmacoeconomics (2005) 23(12):1215-1227.
   PubMed Web of Science ®Google Scholar